The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. CRISPR Therapeutics AG shares valued at $3,613,800 were sold by Kulkarni Samarth on Jan 22 ’26. At $60.23 per share, Kulkarni Samarth sold 60,000 shares. The insider’s holdings dropped to 134,201 shares worth approximately $8.16 million following the completion of this transaction.
Also, Kulkarni Samarth sold 30,000 shares, netting a total of over 1,552,498 in proceeds. Following the sale of shares at $51.75 each, the insider now holds 194,201 shares.
Before that, Samarth Kulkarni had added 60,000 shares to its account. In a trade valued at $3,648,600, the Officer bought CRISPR Therapeutics AG shares for $60.81 each.
As published in their initiating research note from JP Morgan on September 18, 2025, CRISPR Therapeutics AG [CRSP] has been an Overweight and the price target has been revised to $70. Analysts at Evercore ISI upgraded the stock from ‘”an In-line”‘ to ‘”an Outperform”‘ outlook in a report released in mid February. As of February 12, 2025, TD Cowen has increased its “Sell” rating to a “Hold” for CRSP. Earlier on February 03, 2025, H.C. Wainwright initiated its rating. Their recommendation was “a Buy” for CRSP stock.
Analyzing CRSP Stock Performance
On last trading session, CRISPR Therapeutics AG [NASDAQ: CRSP] rose 11.11% to $60.81. The stock’s lowest price that day was $54.22, but it reached a high of $60.86 in the same session. During the last five days, there has been a surge of approximately 6.89%. Over the course of the year, CRISPR Therapeutics AG shares have jumped approximately 46.49%.
Is CRISPR Therapeutics AG subject to short interest?
Stocks of CRISPR Therapeutics AG saw a sharp steep in short interest on 2025-12-31 dropping by -1.38 million shares to 21.05 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 22.43 million shares. A decline of -6.56% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 12.77 of the overall float, the days-to-cover ratio (short ratio) decline to 12.77.
Which companies own the most shares of CRISPR Therapeutics AG (CRSP)?
In terms of CRISPR Therapeutics AG share price expectations, FactSet research, analysts set an average price target of 74 in the next 12 months, up nearly 35.21% from the previous closing price of $54.73. Analysts anticipate CRISPR Therapeutics AG stock to reach 75 by 2026, with the lowest price target being 50. In spite of this, 8 analysts ranked CRISPR Therapeutics AG stock as Buy at the end of 2026. On August 06, 2024, Needham assigned a price target of “a Buy” to the stock and reiterated coverage with a $84.
